Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + leucovorin + 5-fluorouracil + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination regimen consisting of four drugs: - **Trastuzumab** is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), inhibiting HER2-mediated signaling and inducing antibody-dependent cellular cytotoxicity. - **Leucovorin** (folinic acid) enhances the binding of 5-fluorouracil to thymidylate synthase, increasing its cytotoxic effect. - **5-Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription. This combination has been studied as first-line or perioperative therapy for patients with HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma. The addition of trastuzumab to oxaliplatin-based regimens like mFOLFOX6 improves survival outcomes in this population. The regimen acts through both targeted therapy (trastuzumab) and cytotoxic chemotherapy (the other agents)[1][2][7].
- Other names
- trastuzumab plus mFOLFOX6MFOLFOX6+TRAS
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on trastuzumab + leucovorin + 5-fluorouracil + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + leucovorin + 5-fluorouracil + oxaliplatin.